Seeking Alpha

Sanofi (SNY) wins U.S. FDA approval for Aubagio, a pill designed to treat multiple sclerosis,...

Sanofi (SNY) wins U.S. FDA approval for Aubagio, a pill designed to treat multiple sclerosis, making it the second oral therapy that will be available on the U.S. market. The drug will compete with Novartis' (NVS) Gilenya, an oral pill which was approved by the FDA in 2010.
Comments (1)
  • Goeleven
    , contributor
    Comments (629) | Send Message
     
    Finaly SNY got FDA approval for Aubagio. Not so good for NVS
    13 Sep 2012, 06:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs